Show simple item record

dc.contributor.authorPerea, José
dc.contributor.authorGarcía, Juan L
dc.contributor.authorCorchete, Luis
dc.contributor.authorLumbreras, Eva
dc.contributor.authorArriba, María
dc.contributor.authorRueda, Daniel
dc.contributor.authorTapial, Sandra
dc.contributor.authorPérez, Jessica
dc.contributor.authorVieiro, Victoria
dc.contributor.authorRodríguez, Yolanda
dc.contributor.authorBrandáriz, Lorena
dc.contributor.authorGarcía-Arranz, Mariano
dc.contributor.authorGarcía-Olmo, Damián
dc.contributor.authorGoel, Ajay
dc.contributor.authorUrioste, Miguel 
dc.contributor.authorGonzález-Sarmiento, Rogelio
dc.date.accessioned2019-05-17T08:56:55Z
dc.date.available2019-05-17T08:56:55Z
dc.date.issued2019-04-01
dc.identifier.citationInt J Cancer. 2019 ;144(7):1596-1608.es_ES
dc.identifier.issn00207136es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7577
dc.description.abstractTo analyze the possible clonal origin of a part of Synchronous colorectal cancer (SCRC), we studied 104 paired-SCRCs from 52 consecutive patients without hereditary forms of CRC. We used a Single-Nucleotide Polymorphism array to characterize the genomic profiles, and subsequently used a statistical application to define them according to clonality within the same individual. We categorized the ensuing groups according to colonic location to identify differential phenotypes. The SCRC Monoclonal group (M) (19 cases) was divided into Monosegmental (MM) and Pancolonic (MP) groups. The SCRC Polyclonal group (P) (33 cases) was also divided into Monosegmental (PM) and Pancolonic (PP), the first exhibiting preference for left colon. The MM group showed a high rate of mucinous tumors, the lowest mean-number of tumors and associated-polyps, and the worst prognosis. The MP group included the largest mean-number of associated-polyps, best prognosis and familial cancer component. The PM group seemed to be a "frontier" group. Finally, the PP group also exhibited a mucin component, the highest mean-number of tumors (4.6) compared with the mean-number of polyps (7.7), poor prognosis and sporadic cases. Most relevant differential genomic regions within M groups were gains on 1q24 and 8q24, and deletions on 1p21 and 1p23 for MM, while within P were the gains on 7q36 and deletions on 1p36 for PM. The statistical application employed seems to define clonality more accurately in SCRC -more likely to be polyclonal in origin-, and together with the tumor locations, helped us to configure a classification with prognostic and clinical value.es_ES
dc.description.sponsorshipThis work was funded by Projects PI10/00683 and PI16/01650 to J.P, and PI16/01920 to R.G.S, from the Spanish Ministry of Health and Consumer Affairs and FEDER, by Project 2012–0036 from the Mutua Madrileña Foundation, and supported by the CA72851, CA181572, CA184792, CA187956 and CA202797 grants from the National Cancer Institute, National Institute of Health; RP140784 from the Cancer Prevention Research Institute of Texas; grants from the Sammons Cancer Center and Baylor Foundation, as well as funds from the Baylor Scott & White Research Institute, Dallas, TX, USA. We thank the Tumor Registry of the Pathology Department of the 12 de Octubre University Hospital for providing the paraffin‐embedded tissues, and Ron Hartong for his help with the English revision of this manuscript.es_ES
dc.language.isoenges_ES
dc.publisherWiley es_ES
dc.type.hasVersionSMURes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectSingle-Nucleotide Polymorphism array (SNP array)es_ES
dc.subjectSynchronous colorectal canceres_ES
dc.subjectClonalityes_ES
dc.subjectColon locationes_ES
dc.subjectMonoclonales_ES
dc.subjectPolyclonales_ES
dc.titleRedefining synchronous colorectal cancers based on tumor clonalityes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID30151896es_ES
dc.format.volume144es_ES
dc.format.number7es_ES
dc.format.page1596-1608es_ES
dc.identifier.doi10.1002/ijc.31761es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.contributor.funderFundación Mutua Madrileña 
dc.contributor.funderNIH - National Cancer Institute (NCI) (Estados Unidos) 
dc.contributor.funderCancer Prevention and Research Institute of Texas (Estados Unidos) 
dc.contributor.funderBaylor Bear Foundation (Estados Unidos) 
dc.contributor.funderBaylor Scott & White Charles A. Sammons Cancer Center (Estados Unidos) 
dc.contributor.funderBaylor Scott & White Research Institute (Estados Unidos) 
dc.description.peerreviewedNoes_ES
dc.identifier.e-issn1097-0215es_ES
dc.relation.publisherversionhttps://doi.org/10.1002/ijc.31761.es_ES
dc.identifier.journalInternational journal of canceres_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad Clínica de Cáncer Familiares_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI10/00683es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/01650es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/01920es_ES
dc.rights.accessRightsopen accesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional